A groundbreaking study recently published in the reputable oncology journal Oncotarget has revealed a significant genetic link between a specific polymorphism in the PTGS2 gene and benign prostate hyperplasia (BPH) among Lebanese men. This study, led by the research team at Utah Valley University and spearheaded by first author Brock J. Sheehan and corresponding author Ruhul H. Kuddus, marks an important advancement in our understanding of the genetic underpinnings of proliferative prostate diseases. Its findings may not only contribute to earlier identification of at-risk individuals but also pave the way for personalized treatment approaches.
Benign prostate hyperplasia is a chronic, non-cancerous enlargement of the prostate gland, affecting a considerable portion of the aging male population worldwide. Despite its benign nature, BPH has profound implications on quality of life, leading to urinary symptoms and other complications. However, the molecular and genetic mechanisms that predispose individuals to this condition have remained largely obscure, particularly in specific ethnic populations. The recent investigation targeted the prostaglandin-endoperoxide synthase genes, PTGS1 and PTGS2, known to encode the COX-1 and COX-2 isozymes, enzymes centrally involved in inflammation — a suspected factor underpinning many prostatic diseases.
In this study, DNA samples were collected from 168 Lebanese men, categorized into three groups: those diagnosed with prostate cancer, individuals with BPH, and a control group of healthy participants. Through a meticulously designed single nucleotide polymorphism (SNP) association analysis, the researchers evaluated two specific genetic variants — one each in the PTGS1 and PTGS2 genes. Remarkably, their data demonstrated no significant association of the PTGS1 variant with either prostate cancer or BPH, suggesting that this isozyme might play a lesser role in the pathogenesis of these conditions.
Conversely, the PTGS2 gene polymorphism, particularly the -765 G>C SNP, exhibited a substantial correlation with BPH. Men harboring the C allele of this polymorphism displayed more than double the odds of developing BPH compared to non-carriers, with an odds ratio of 2.30 and a p-value indicating strong statistical significance. While there was a parallel but less definitive trend observed in those with prostate cancer, the evidence firmly positions the PTGS2 variant as a critical genetic factor in BPH development within this population.
The PTGS2 gene encodes cyclooxygenase-2 (COX-2), an enzyme inducible during inflammatory processes, catalyzing the conversion of arachidonic acid to prostaglandins — lipid compounds that mediate inflammation and cell proliferation. The -765 G>C polymorphism is located in the promoter region of the gene, influencing the gene’s expression levels. Previous research has linked this polymorphism with various malignancies, including colorectal, gastric, and prostate cancers, underscoring its biological significance in pathological cell growth and inflammatory regulation.
Notably, inflammation has emerged as a pivotal contributor to the pathophysiology of BPH and prostate cancer, partly through promoting aberrant cellular proliferation and tissue remodeling. This research adds substantial evidence to the inflammatory hypothesis by highlighting a genetic variant that may modulate COX-2 expression, thereby affecting susceptibility to prostate gland diseases. Unraveling such molecular associations is crucial to understanding disease etiology across different populations, with genetic variability potentially influencing disease risk and therapeutic responses.
The cohort-centric nature of the study, focusing on Lebanese men, also emphasizes the importance of population-specific genetic studies. Ethnic and regional genetic heterogeneity frequently modulate the frequency and impact of gene variants, and their association with diseases can vary. Hence, findings from this research may inform regionally tailored screening protocols, contributing to personalized medicine paradigms in Middle Eastern populations.
In terms of clinical implications, the discovery of the strong association between the PTGS2 -765 C allele and BPH risk could influence diagnostic and therapeutic strategies. Genetic screening for this variant may help identify men at an elevated risk of developing BPH before the onset of clinical symptoms, facilitating early intervention. Additionally, the role of COX-2 inhibitors, such as nonsteroidal anti-inflammatory drugs (NSAIDs), may be revisited, given that these agents directly target the enzyme encoded by PTGS2. Tailoring COX-2 inhibitor therapy based on PTGS2 genotype could potentially enhance treatment efficacy and minimize adverse effects.
Despite the promising findings, the authors acknowledge several limitations, particularly the modest sample size and the need for replication of results in larger, more ethnically diverse cohorts. Genetic studies in prostate diseases have historically faced challenges related to heterogeneity in study design, population structure, and environmental factors. Accordingly, multicenter studies with comprehensive genomic and transcriptomic analyses will be vital to validate these associations and explore underlying mechanisms.
Furthermore, while the study zeroed in on two common SNPs, the complexity of genetic contributions to prostate diseases likely involves numerous other loci and gene-gene interactions. Integrative approaches incorporating genome-wide association studies (GWAS), epigenetics, and proteomics may provide a more holistic view of the molecular networks operational in BPH and prostate cancer.
The potential for such research extends beyond academic interest; it touches on public health aspects, considering the high prevalence of BPH among men over 60 years old globally. Early genetic markers can drive population-level screening initiatives, potentially reducing the burden of late-stage disease management. Moreover, precision medicine initiatives increasingly rely on genetic insights like those presented to optimize therapeutic regimens and improve patient outcomes.
In conclusion, this seminal work describing the association of the PTGS2 -765 G>C SNP with benign prostate hyperplasia offers new avenues for genetic screening, risk stratification, and targeted therapy in prostate diseases. By illuminating the genetic factors influencing prostate pathology in Lebanese men, the study adds a critical piece to the puzzle of inflammation-mediated prostate disorders. As further research validates and expands upon these findings, the promise of personalized medicine in urology comes into sharper focus, heralding improvements in both preventive and therapeutic frameworks for millions of men worldwide.
Subject of Research: People
Article Title: Association between two single nucleotide polymorphisms of the Prostaglandin-Endoperoxide Synthase 1 and 2 genes and cell proliferative prostatic diseases in Lebanon
News Publication Date: April 4, 2025
Web References:
- Oncotarget Archive, Volume 16: https://www.oncotarget.com/archive/v16/
- DOI link: http://dx.doi.org/10.18632/oncotarget.28710
References: None explicitly provided beyond journal citation
Image Credits: Copyright © 2025 Rapamycin Press LLC dba Impact Journals
Keywords: cancer, PTGS1 and PTGS2 genes, COX-1 and COX-2 isozymes, single nucleotide polymorphism association study, prostate cancer, benign prostate hyperplasia (BPH)
